A recent published study by Professor Robert Bucki and colleagues has shown that CSA-131 has broad spectrum antifungal activity and
Latest News
News
News
Colistin is the last agent used to combat bacteria that are resistant to the strongest antibiotics. Colistin has remained the
A recent published study by Professor Jordi Vila and his colleagues at the University of Barcelona, Spain has found that
N8 Medical News
Here you will find the latest information, including: press releases, events and presentations and blog posts.
Newsletter Sign-up
Interested in hearing whats new with N8 Medical? Sign-up to join our newsletter.
Recent Posts
- N8 Medical and USAMRIID Enter CRADA to Test CSA Compounds Against Anthrax and other Biodefense Pathogens
- FDA grants QIDP Designation For Kinnear’s CSA-131 drug for Life-threatening Pseudomonas Bacterial Infections in CF
- NIH Awards N8 Medical Two Additional SBIR Grants to Develop CeraShieldTM Coated Hemodialysis Catheters and Pedicle Screws
- N8 Medical Is Awarded Almost $2 Million in Phase II SBIR Grant
- N8 Medical Announces its CeraShield™ Coating inhibits COVID-19 Virus Growth on Endotracheal Tubes
Contact us
Lets Get in Touch!
- info@n8medical.com
- N8 Medical LLC - 545 Metro Place, Dublin, OH, 43107
Follow now
mynewform
Basic contact form
N8 Medical, Inc. (N8 Medical) is a clinical-stage medical device company focused on commercializing medical devices that incorporate a novel class of active compounds called ceragenins.The subsidiaries for N8 Medical Inc are N8 Medical, LLC for Medical Device Development and Kinnear Pharmaceuticals, LLC for drug development.